Johnson & Johnson (JNJ) Free Cash Flow (FCF): $19.70B
The free cash flow (FCF) for Johnson & Johnson (JNJ) is $19.70B. It is below its 12-month average by 0.36% ($19.77B).
JNJ Free Cash Flow (FCF) Chart
JNJ Average Free Cash Flow (FCF) Chart
JNJ Current vs Average Free Cash Flow (FCF) Chart
JNJ Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$19.70B
FREE CASH FLOW (FCF) AVG TTM
$19.77B
FREE CASH FLOW (FCF) AVG 3Y
$18.74B
FREE CASH FLOW (FCF) AVG 5Y
$19.15B
FREE CASH FLOW (FCF) AVG 10Y
$18.41B
FREE CASH FLOW (FCF) AVG 15Y
$16.81B
FREE CASH FLOW (FCF) AVG 20Y
$15.61B
CURRENT VS TTM AVG
-0.36%
CURRENT VS 3Y AVG
+5.09%
CURRENT VS 5Y AVG
+2.84%
CURRENT VS 10Y AVG
+7.00%
CURRENT VS 15Y AVG
+17.19%
CURRENT VS 20Y AVG
+26.21%
FCF Analysis
Free Cash Flow (TTM)
$19.70B
FCF Yield
3.07%
Price/FCF
32.6
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Johnson & Johnson Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Johnson & Johnson (JNJ)?
- The free cash flow (FCF) for JNJ stock is $19.70B.
- What is the TTM average free cash flow (FCF) for Johnson & Johnson (JNJ)?
- The TTM average free cash flow (FCF) for JNJ stock is $19.77B.
- What is the 3Y average free cash flow (FCF) for Johnson & Johnson (JNJ)?
- The 3Y average free cash flow (FCF) for JNJ stock is $18.74B.
- What is the 5Y average free cash flow (FCF) for Johnson & Johnson (JNJ)?
- The 5Y average free cash flow (FCF) for JNJ stock is $19.15B.
- What is the 10Y average free cash flow (FCF) for Johnson & Johnson (JNJ)?
- The 10Y average free cash flow (FCF) for JNJ stock is $18.41B.
- What is the 15Y average free cash flow (FCF) for Johnson & Johnson (JNJ)?
- The 15Y average free cash flow (FCF) for JNJ stock is $16.81B.
- What is the 20Y average free cash flow (FCF) for Johnson & Johnson (JNJ)?
- The 20Y average free cash flow (FCF) for JNJ stock is $15.61B.
Johnson & Johnson Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-28 | $19.70B |
| 2024-12-29 | $19.84B |
| 2023-12-31 | $18.25B |
| 2023-01-01 | $17.18B |
| 2022-01-02 | $19.76B |
| 2021-01-03 | $20.19B |
| 2019-12-31 | $19.92B |
| 2018-12-31 | $18.53B |
| 2017-12-31 | $17.78B |
| 2016-12-31 | $15.54B |
| 2015-12-31 | $15.82B |
| 2014-12-31 | $14.76B |
| 2013-12-31 | $13.82B |
| 2012-12-31 | $12.46B |
| 2011-12-31 | $11.40B |
| 2010-12-31 | $14.00B |
| 2009-12-31 | $14.21B |
| 2008-12-31 | $11.91B |
| 2007-12-31 | $11.94B |
| 2006-12-31 | $11.51B |
| 2005-12-31 | $9.24B |
| 2004-12-31 | $8.96B |
| 2003-12-31 | $8.33B |
| 2002-12-31 | $6.08B |
| 2001-12-31 | $7.13B |
| 2000-12-31 | $4.92B |
| 1999-12-31 | $3.68B |
| 1998-12-31 | $-55.00M |
| 1997-12-31 | $2.95B |
| 1996-12-31 | $2.52B |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato